Drug Search Results
More Filters [+]

AZD-9819

Alternative Names: azd-9819, azd9819, azd 9819
Latest Update: 2011-11-09
Latest Update Note: Clinical Trial Update

Product Description

a human neutrophil elastase inhibitor

Mechanisms of Action: NE Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Inhalant

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AZD-9819

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

D3020C00001

P1

Completed

Healthy Volunteers

2011-01-01

Recent News Events

Date

Type

Title